Apex AI has a three-stage international expansion plan focusing on Korea, the U.S., and Japan, followed by a broader global rollout.
Clinical validation with major hospitals, including:
Seoul National University Bundang Hospital
Inha University Hospital
Hanlim University Sacred Heart Hospital
Initial rollout in health screening centers with direct sales and platform partnerships.
AI-powered digestive health monitoring collaboration with Next Biomed & iKooB.
Pilot program in Utah (Phase 2 region) before expanding to key medical hubs like New York, California, Boston, and Texas.
Strategic collaborations with top-tier U.S. institutions, including:
Harvard Medical School (MGH) – Two professors onboarding as advisors.
Oracle Healthcare – AI integration partnerships.
Medtronic – Exploring collaboration on medical AI devices.
Investment network expansion – Attracting U.S.-based investors to establish a sustainable market presence.
AI licensing to endoscopy manufacturers, including Olympus, Pentax, and Fujifilm.
Partnership with CEC (Fujitsu subsidiary) to penetrate Japanese medical institutions.
Regulatory alignment for market approval and expansion into hospitals & screening centers.
Following successful market entries in Korea, the U.S., and Japan, Apex AI will scale into Europe, China, and other high-demand regions.
Cloud-based AI diagnostics will drive accessibility, making Apex AI a global leader in AI-powered gastrointestinal cancer detection.